Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$830M |
| 2 |
UnitedHealth
UNH
|
+$769M |
| 3 |
Arthur J. Gallagher & Co
AJG
|
+$691M |
| 4 |
Amazon
AMZN
|
+$654M |
| 5 |
Bank of America
BAC
|
+$634M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.23B |
| 2 |
NVIDIA
NVDA
|
+$550M |
| 3 |
Spotify
SPOT
|
+$473M |
| 4 |
Citigroup
C
|
+$460M |
| 5 |
Boston Scientific
BSX
|
+$428M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 3.13% |
| 2 | Technology | 2.97% |
| 3 | Financials | 2.19% |
| 4 | Consumer Discretionary | 2.09% |
| 5 | Industrials | 1.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
11151
Lantern Pharma
LTRN
$33.9M
| $120K | ﹤0.01% |
37,587
+35,434
| +1,646% | +$121K |
|
11152
PUT
Resideo Technologies
REZI
$3.11B
| $120K | ﹤0.01% |
5,200
-2,100
| -29% | -$49.2K |
|
11153
PUT
AMC Global Media
AMCX
$510M
| $120K | ﹤0.01% |
12,100
-5,500
| -31% | -$48.6K |
|
11154
KORU Medical Systems
KRMD
$157M
| $120K | ﹤0.01% |
31,111
-82,198
| -73% | -$267K |
|
11155
CALL
Zegna
ZGN
$3.69B
| $120K | ﹤0.01% |
14,500
-27,500
| -65% | -$225K |
|
|
DDL
11156
CALL
Dingdong
DDL
$523M
| $120K | ﹤0.01% |
36,500
+36,300
| +18,150% | +$140K |
|
11157
DMC Global
BOOM
$155M
| $120K | ﹤0.01% |
16,280
-17,030
| -51% | -$161K |
|
11158
CALL
Invesco S&P 500 Pure Growth ETF
RPG
$2.1B
| $120K | ﹤0.01% |
2,900
+2,700
| +1,350% | +$112K |
|
|
CLYM
11159
Climb Bio
CLYM
$938M
| $120K | ﹤0.01% |
+66,472
| New | +$241K |
|
11160
PUT
Wheels Up
UP
$182M
| $120K | ﹤0.01% |
3,625
+2,155
| +147% | +$90.7K |
|
11161
CALL
Liquidity Services
LQDT
$1.36B
| $119K | ﹤0.01% |
3,700
-3,100
| -46% | -$78.6K |
|
11162
Creative Realities
CREX
$43M
| $119K | ﹤0.01% |
48,764
+17,238
| +55% | +$63.6K |
|
11163
PUT
Four Corners Property Trust
FCPT
$2.77B
| $119K | ﹤0.01% |
4,400
-2,900
| -40% | -$82.7K |
|
11164
CALL
Suzano
SUZ
$9.99B
| $119K | ﹤0.01% |
11,800
-9,600
| -45% | -$98.3K |
|
11165
CALL
Kura Oncology
KURA
$966M
| $119K | ﹤0.01% |
13,700
+4,000
| +41% | +$57.6K |
|
11166
PUT
Larimar Therapeutics
LRMR
$453M
| $119K | ﹤0.01% |
30,800
+1,400
| +5% | +$9.24K |
|
11167
PUT
PRA Group
PRAA
$776M
| $119K | ﹤0.01% |
5,700
-10,300
| -64% | -$220K |
|
11168
PUT
Tecnoglass Holdings
TGLS
$1.86B
| $119K | ﹤0.01% |
1,500
-10,200
| -87% | -$776K |
|
11169
PUT
Immunome
IMNM
$3.09B
| $119K | ﹤0.01% |
11,200
+2,800
| +33% | +$33.8K |
|
11170
PUT
Clarivate
CLVT
$1.23B
| $119K | ﹤0.01% |
23,400
+7,500
| +47% | +$43.2K |
|
|
BLDP
11171
PUT
Ballard Power Systems
BLDP
$814M
| $119K | ﹤0.01% |
71,600
+37,900
| +112% | +$59K |
|
|
DGXX
11172
Digi Power X Inc
DGXX
$391M
| $119K | ﹤0.01% |
79,150
+8,499
| +12% | +$13.9K |
|
11173
CALL
Gaia
GAIA
$37.1M
| $119K | ﹤0.01% |
+26,400
| New | +$144K |
|
11174
CALL
State Street SPDR Portfolio Mortgage Backed Bond ETF
SPMB
$7.05B
| $119K | ﹤0.01% |
+5,500
| New | +$120K |
|
11175
SCYNEXIS
SCYX
$51.5M
| $118K | ﹤0.01% |
+12,242
| New | +$127K |
|
Similar funds
Ken Griffin's Q4 2024 Portfolio in Review
As of Q4 2024, Ken Griffin held 15,826 positions worth $578B, up 11% from $518B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Ken Griffin deployed $35.2B of net new capital in Q4 2024, opening 1,745 new positions and adding to 6,428 existing holdings. Its largest new stake was Zoetis: 1,090,499 shares worth $178M.
By sector, the portfolio is most concentrated in Healthcare at 3.1% of assets, up from 2.9% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $1.23B trimmed.
- Ken Griffin's largest Q4 2024 buy was Zoetis: 1,090,499 shares worth $178M.
- Ken Griffin added most to Boeing in Q4 2024, an estimated $830M increase.
- Ken Griffin's biggest Q4 2024 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.23B.
- Ken Griffin fully exited Spotify in Q4 2024, selling an estimated $473M.
- Ken Griffin's ten largest holdings make up 31% of its $578B portfolio in Q4 2024.
- Ken Griffin opened 1,745 new positions and closed 1,423 in Q4 2024.
- Ken Griffin's portfolio value rose 11% quarter-over-quarter to $578B.
Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.